Obsidian Therapeutics, Inc. news

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022.

The data to be presented outline next-genera

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the 

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. The data to be presented demonstrate tight control of membrane bound or shed IL12 (a proinflammatory cytokine whose potential clinical utility has been limited by

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event will be hosted live in Washington, D.C. and virtually from November 10-14, 2021.

T

Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology (ESMO) Congress, which will be hosted virtually September 16-21, 2021.

The abstract for the poster describes how Obsidian’s cytoTIL15 product (TIL engineered with membrane-bound IL15, or mbIL15) demonstrates enhanced in vitro potenc